...
首页> 外文期刊>Journal of Controlled Release: Official Journal of the Controlled Release Society >Doxorubicin-induced co-assembling nanomedicines with temperature-sensitive acidic polymer and their in-situ-forming hydrogels for intratumoral administration
【24h】

Doxorubicin-induced co-assembling nanomedicines with temperature-sensitive acidic polymer and their in-situ-forming hydrogels for intratumoral administration

机译:阿霉素诱导的纳米药物与温度敏感型酸性聚合物的共组装及其在肿瘤内给药的原位形成水凝胶

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Doxorubicin (DOX)-induced co-assembling nanomedicines (D-PNAx) with temperature-sensitive PNAx triblock polymers have been developed for regional chemotherapy against liver cancer via intratumoral administration in the present work. Owing to the formation of insoluble DOX carboxylate, D-PNAx nanomedicines showed high drug-loading and entrapment efficacy via a simple mixing of doxorubicin hydrochloride and PNAx polymers. The sustained releasing profile of D-PNA100 nanomedicines indicated that only 9.4% of DOX was released within 1 day, and 60% was released during 10 days. Based on DOX-induced co-assembling behavior and their temperature sensitive in-situ-forming hydrogels, D-PNA100 nanomedicines showed excellent antitumor activity against H22 tumor using intratumoral administration. In contrast to that by free DOX solution (1.13 +/- 0.04 times at 9 days) and blank PNA100 (2.11 +/- 0.34 times), the tumor volume treated by D-PNA100 had been falling to only 0.77 +/- 0.13 times of original tumor volume throughout the experimental period. In vivo biodistribution of DOX indicated that D-PNA100 nanomedicines exhibited much stronger DOX retention in tumor tissues than free DOX solution via intratumoral injection. D-PNA100 nanomedicines were hopeful to be developed as new temperature sensitive in-situ-forming hydrogels via i.t. injection for regional chemotherapy. (C) 2016 Published by Elsevier B.V.
机译:在本工作中,已经开发出阿霉素(DOX)诱导的与温度敏感的PNAx三嵌段聚合物共组装的纳米药物(D-PNAx)用于针对肝癌的区域化疗,方法是通过肿瘤内给药。由于不溶性DOX羧酸盐的形成,D-PNAx纳米药物通过简单地将盐酸阿霉素和PNAx聚合物混合,显示出很高的载药量和截留率。 D-PNA100纳米药物的持续释放曲线表明,在1天内仅释放9.4%的DOX,在10天内释放了60%的DOX。基于DOX诱导的共组装行为及其对温度敏感的原位形成的水凝胶,D-PNA100纳米药物通过瘤内给药对H22肿瘤表现出优异的抗肿瘤活性。与自由DOX溶液(9天时为1.13 +/- 0.04倍)和空白PNA100(2.11 +/- 0.34倍)相比,D-PNA100治疗的肿瘤体积仅下降至0.77 +/- 0.13倍在整个实验期间的原始肿瘤体积。 DOX的体内生物分布表明,D-PNA100纳米药物在肿瘤组织中的DOX保留能力比通过肿瘤内注射的游离DOX溶液强得多。 D-PNA100纳米药物有望通过i.t.被开发为新型的温度敏感原位形成水凝胶。注射用于局部化疗。 (C)2016由Elsevier B.V.发布

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号